Physiologically based pharmacokinetic modeling of cyclohexane as a tool for integrating animal and human test data.
Int J Toxicol. 2009 Nov-Dec; 28(6):498-509.IJ
This report describes a physiologically based pharmacokinetic model for cyclohexane and its use in comparing internal doses in rats and volunteers following inhalation exposures. Parameters describing saturable metabolism of cyclohexane are measured in rats and used along with experimentally determined partition coefficients. The model is evaluated by comparing predicted blood and brain concentrations to data from studies in rats and then allometrically scaling the results to humans. Levels of cyclohexane in blood and exhaled air are measured in human volunteers and compared with model values. The model predicts that exposure of volunteers to cyclohexane at levels of 4100 mg/m(3) (approximately 1200 ppm) will result in brain levels similar to those in rats exposed to 8000 mg/m(3) (the no-effect level for acute central nervous system effects). There are no acute central nervous system effects in humans exposed to 860 mg/m(3), consistent with model predictions that current occupational exposure levels for cyclohexane protect against acute central nervous system effects.
Hissink AM
TNO Quality of Life, Zeist, The Netherlands.
Kulig BM
Kruse J
Freidig AP
Verwei M
Muijser H
Lammers JH
McKee RH
Owen DE
Sweeney LM
Salmon F
AlgorithmsAnimalsBrainCyclohexanesData Interpretation, StatisticalHumansMaleModels, StatisticalNo-Observed-Adverse-Effect LevelOccupational ExposurePharmacokineticsPulmonary AlveoliRatsRats, Inbred F344Rats, WistarSolventsSpecies SpecificityTemperatureTissue DistributionYoung Adult
Hissink, A M., et al. "Physiologically Based Pharmacokinetic Modeling of Cyclohexane as a Tool for Integrating Animal and Human Test Data." International Journal of Toxicology, vol. 28, no. 6, 2009, pp. 498-509.
Hissink AM, Kulig BM, Kruse J, et al. Physiologically based pharmacokinetic modeling of cyclohexane as a tool for integrating animal and human test data. Int J Toxicol. 2009;28(6):498-509.
Hissink, A. M., Kulig, B. M., Kruse, J., Freidig, A. P., Verwei, M., Muijser, H., Lammers, J. H., McKee, R. H., Owen, D. E., Sweeney, L. M., & Salmon, F. (2009). Physiologically based pharmacokinetic modeling of cyclohexane as a tool for integrating animal and human test data. International Journal of Toxicology, 28(6), 498-509. https://doi.org/10.1177/1091581809348718
Hissink AM, et al. Physiologically Based Pharmacokinetic Modeling of Cyclohexane as a Tool for Integrating Animal and Human Test Data. Int J Toxicol. 2009 Nov-Dec;28(6):498-509. PubMed PMID: 19966142.
TY - JOUR T1 - Physiologically based pharmacokinetic modeling of cyclohexane as a tool for integrating animal and human test data. AU - Hissink,A M, AU - Kulig,B M, AU - Kruse,J, AU - Freidig,A P, AU - Verwei,M, AU - Muijser,H, AU - Lammers,J H C M, AU - McKee,R H, AU - Owen,D E, AU - Sweeney,L M, AU - Salmon,F, PY - 2009/12/8/entrez PY - 2009/12/8/pubmed PY - 2010/2/18/medline SP - 498 EP - 509 JF - International journal of toxicology JO - Int J Toxicol VL - 28 IS - 6 N2 - This report describes a physiologically based pharmacokinetic model for cyclohexane and its use in comparing internal doses in rats and volunteers following inhalation exposures. Parameters describing saturable metabolism of cyclohexane are measured in rats and used along with experimentally determined partition coefficients. The model is evaluated by comparing predicted blood and brain concentrations to data from studies in rats and then allometrically scaling the results to humans. Levels of cyclohexane in blood and exhaled air are measured in human volunteers and compared with model values. The model predicts that exposure of volunteers to cyclohexane at levels of 4100 mg/m(3) (approximately 1200 ppm) will result in brain levels similar to those in rats exposed to 8000 mg/m(3) (the no-effect level for acute central nervous system effects). There are no acute central nervous system effects in humans exposed to 860 mg/m(3), consistent with model predictions that current occupational exposure levels for cyclohexane protect against acute central nervous system effects. SN - 1092-874X UR - https://www.unboundmedicine.com/medline/citation/19966142/Physiologically_based_pharmacokinetic_modeling_of_cyclohexane_as_a_tool_for_integrating_animal_and_human_test_data_ L2 - https://journals.sagepub.com/doi/10.1177/1091581809348718?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -
Grapherence [↓2]
Cyclohexanes
Models, Statistical
No-Observed-Adverse-Effect Level
Pulmonary Alveoli
Rats, Inbred F344
Rats, Wistar
Species Specificity
Model studies for evaluating the neurobehavioral effects of complex hydrocarbon solvents III. PBPK modeling of white spirit constituents as a tool for integrating animal and human test data.
Neurobehavioral effects of cyclohexane in rat and human.
A comparison of physiologically based pharmacokinetic model predictions and experimental data for inhaled ethanol in male and female B6C3F1 mice, F344 rats, and humans.
Genotoxicity of 1,3-butadiene and its epoxy intermediates.
Determination of age and gender differences in biochemical processes affecting the disposition of 2-butoxyethanol and its metabolites in mice and rats to improve PBPK modeling.
Development of a physiologically based pharmacokinetic model for propylene glycol monomethyl ether and its acetate in rats and humans.
Modeling the toxicokinetics of inhaled toluene in rats: influence of physical activity and feeding status.
Development of physiologically based pharmacokinetic model for methyl tertiary-butyl ether and tertiary-butanol in male Fisher-344 rats.
Predicting age-appropriate pharmacokinetics of six volatile organic compounds in the rat utilizing physiologically based pharmacokinetic modeling.
Physiologically based pharmacokinetic modeling of a ternary mixture of alkyl benzenes in rats and humans.